Our goal is to address serious medical conditions, across multiple and diverse therapeutic areas. Our
FDA-approved medicines are only the beginning of our long-term commitment to solve the human body's
most complex mysteries.
To achieve our mission to repeatedly bring important new medicines to patients with serious diseases, we remain committed to running our business responsibly and operating with the highest standards of integrity. This commitment underscores our philosophy of ‘doing well by doing good,’ every day.
Professor, Departments of Pediatrics, Molecular & Human Genetics, and Neurology & Neuroscience, Baylor College Director, Jan & Dan Duncan Neurological Research Institute at Texas Children's Hospital
Huda Y. Zoghbi, M.D., joined the Board in September 2016. Dr. Zoghbi is a professor in the departments of Pediatrics, Molecular and Human Genetics, and Neurology and Neuroscience at Baylor College of Medicine, the director of the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, and an investigator of the Howard Hughes Medical Institute. Dr. Zoghbi has been elected to the National Academy of Sciences, the Institute of Medicine and the American Association for the Advancement of Science. She has been awarded numerous recognitions for her work including the Pearl Meister Greengard Prize, the March of Dimes Prize in Developmental Biology and the Vanderbilt Prize in Biomedical Science.
Dr. Zoghbi earned her B.Sc. from the American University of Beirut, received her M.D. from Meharry Medical College in Nashville, Tennessee, and completed her pediatrics residency and a joint residency in neurology and pediatric neurology at Baylor College of Medicine, where she then pursued postdoctoral research training in molecular genetics.